Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Decoy Therapeutics Inc. DCOY

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$-12.5M
$-5.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2022 · Revenue 0.0 · Net income -31.6
2M4M-15M-30M
20152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2021 · Operating -696.3% · Net -693.8%
-1000%-2000%-3000%
201520202025
ROE
FY2025 · ROE -338.3%
-100%-200%-300%
201520202025
Three returns, three denominators.

Each USD of equity lost 338 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -5.4
2M3M-15M-30M
201520202025
Net buybacks $ Dividends $
FY2020 · Dividends 0.0 · Net buybacks ·
50000100000
201820192020

Total assetsUSD 11.1M
EquityUSD 5.9M
CashUSD 10.7M
Current ratio2.13×

Equity funds 53% of total assets.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
DCOY, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue $B◌◌◌0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.0◌◌◌◌◌0.0◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0◌◌−0.0−0.0−0.00.0−0.0−0.0−0.0
EPS, diluted $−129.10−69.54−30.74−14.88−7.72−0.50−2.12−1.16−1.99−2.43−2.08
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌
Payout %—————−0−2−0———
ROE %−338.3−164.0−160.1−128.7−41.9−44.9———−52.1—
Shares out B◌0.000.000.000.050.020.000.020.020.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 47 reconciliationsAUDITED

Reconciled in 10 of the 11 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 14 checks were skipped: the balance sheet is not tagged before 2014. Eight checks were skipped: EPS is not tagged before 2015. Eight checks were skipped: revenue is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image